Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR | Q13258 | 7/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 5/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869923 | 0.89 | PTGDR (0.39) | PTGDRENPP3ENPP1ENPP2CA2 | |
| SCHEMBL6865578 | 0.86 | PTGDR (0.51) | PTGDRTBXA2R | |
| SCHEMBL7639754 | 0.78 | PTGDR (0.35) | PTGDRFAAHTBXA2RMAPTMEN1 | |
| SCHEMBL6869920 | 0.75 | PTGDR (0.56) | PTGDRTBXA2R | |
| SCHEMBL4643044 | 0.74 | CA2 (0.45) | ENPP3ENPP1ENPP2CA2CA9 | |
| SCHEMBL3977036 | 0.74 | CA12 (0.47) | ENPP3ENPP1ENPP2CA2ALDH1A1 | |
| SCHEMBL14462523 | 0.72 | CA12 (0.45) | ENPP3ENPP1ENPP2CA2ALDH1A1 | |
| SCHEMBL6232289 | 0.72 | CA12 (0.45) | ENPP3ENPP1ENPP2CA2ALDH1A1 | |
| SCHEMBL5176774 | 0.71 | PTGDR (0.74) | PTGDRTBXA2R | |
| SCHEMBL6233312 | 0.69 | CYP2A6 (0.49) | CA2ALDH1A1SMN1; SMN2CA12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1069123-B1 | PROCESS FOR PRODUCING BENZOTHIOPHENECARBOXYLIC ACID AMIDE DERIVATIVES | SHIONOGI & CO (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-6465662-B1 | OXIDIZING 2-HYDROXYETHYL-10 NORPINAN-3-YL)-2-AMINE AMIDES OF OXY-SUBSTITUTED BENZOTHIOPHENECARBOXYLIC ACIDS TO FORM ALDEHYDES IN THE PRESENCE OF 2,2,6,6-TETRAMETHYLPIPERIDINE-1-OXYLS. | SHIONOGI & CO., LTD. (JP) | 2002-10-15 | — | — | US | disclosed |
| US-20020115871-A1 | Process for preparing benzothiophenecarboxamide derivatives | OKADA TETSUO (JP) | 2002-08-22 | — | — | US | disclosed |
| US-6399788-B1 | AMIDATION | SHIONOGI & CO., LTD. (JP) | 2002-06-04 | — | — | US | disclosed |
| EP-1069123-A1 | PROCESS FOR PRODUCING BENZOTHIOPHENECARBOXYLIC ACID AMIDE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115871-A1 | Process for preparing benzothiophenecarboxamide derivatives | PGD, HPD, PTGS2 | PTGDR 11/4885ENPP3 2184/4885ENPP1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.